Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.40 |
| ▸ | CA2 | P00918 | 10/20 | 0.40 |
| ▸ | CA9 | Q16790 | 10/20 | 0.40 |
| ▸ | CA1 | P00915 | 9/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700164 | 0.87 | CA12 (0.37) | CA12CA2CA9CA1CA14 | |
| SCHEMBL5700314 | 0.81 | SLC22A12 (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL5700440 | 0.76 | SLC22A12 (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL8148133 | 0.72 | CA12 (0.43) | CA12CA2CA9CA1CA14 | |
| SCHEMBL29890659 | 0.72 | PTGS2 (0.41) | CA12CA2CA9POLB | |
| SCHEMBL18297463 | 0.72 | PTGS2 (0.41) | CA12CA2CA9POLB | |
| SCHEMBL15823128 | 0.72 | RARB (0.42) | CA12CA2CA9LMNAPOLB | |
| SCHEMBL5700438 | 0.71 | CA12 (0.46) | CA12CA2CA9CA1CA14 | |
| SCHEMBL5700130 | 0.71 | CYP17A1 (0.42) | CA12CA2CA9CA1CA14 | |
| SCHEMBL5700539 | 0.71 | CA12 (0.42) | CA12CA2CA9CA1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | CA12 1841/4885CA2 2561/4885CA9 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.